#156377

Anti-P-glycoprotein [UIC2]

Cat. #156377

Anti-P-glycoprotein [UIC2]

Cat. #: 156377

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: P-glycoprotein

Class: Monoclonal

Application: IP ; IF ; IHC ; FACS

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: University of Illinois Chicago

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-P-glycoprotein [UIC2]
  • Alternate name: ABCB1, ABC2, CD243, CLCS, GP17, MDR1, P-GP, PGY1, ATP binding cassette subfamily B member 1, P-glycoprotein, P-gp, Pgp
  • Research fields: Cancer;Cell signaling and signal transduction;Stem cell biology
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: IP ; IF ; IHC ; FACS
  • Description: Genetic variations in P-glycoprotein are associated with susceptibility to inflammatory bowel disease type 13 (IBD13) [MIM:612244]. Inflammatory bowel disease is characterized by a chronic relapsing intestinal inflammation. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may involve any part of the gastrointestinal tract, but most frequently the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints. Crohn disease and ulcerative colitis are commonly classified as autoimmune diseases.
  • Immunogen: Mouse Balb/c 3T3 fibroblasts transfected with human P-Glycoprotein cDNA
  • Recommended controls: IgG2a

Target Details

  • Target: P-glycoprotein
  • Tissue cell line specificity: IgG2a
  • Target background: Genetic variations in P-glycoprotein are associated with susceptibility to inflammatory bowel disease type 13 (IBD13) [MIM:612244]. Inflammatory bowel disease is characterized by a chronic relapsing intestinal inflammation. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may involve any part of the gastrointestinal tract, but most frequently the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints. Crohn disease and ulcerative colitis are commonly classified as autoimmune diseases.

Applications

  • Application: IP ; IF ; IHC ; FACS

Handling

  • Format: Liquid
  • Unit size: 100 ug
  • Shipping conditions: Shipping at 4° C

References

  • Deaton et al. 1978. Front Nurs Serv Q Bull. 53(4):30-1. PMID: 352877.